Skip to content

Clinical Trial of Evidenced-based Evaluation of Zhenjing Dingzhi Granule in the Treatment of Depression Related Insomnia

Clinical Trial of Evidenced-based Evaluation of Zhenjing Dingzhi Granule in the Treatment of Depression Related Insomnia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077960
Enrollment
Unknown
Registered
2023-11-24
Start date
2023-11-30
Completion date
Unknown
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression Related Insomnia

Interventions

control group:Fluoxetone(trade name: Prozac 20mg/tablet Lilly Suzhou Pharmaceutical Approval numberJ20130010)was adminsrtatered orally once a day with 20mg each time for 8 weeks before treatment. Zhen
treatment group:Fluoxetone(trade name: Prozac 20mg/tablet Lilly Suzhou Pharmaceutical Approval numberJ20130010)was adminsrtatered orally once a day with 20mg each time for 8 weeks before treatment. Zh

Sponsors

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1)Age 18-65 years old, gender unlimited; (2)Insomnia as the main complaint, in line with the DSM-V insomnia dignosis article 1-7; (3)It met the diagnostic criteria of the international classification dieases(ICD-10) for mild to moderate depression, and scored 27 points on the Hamilton Depression Scale(17-item edition), and =24 points. (4)In line with the TCM diagnostic criteria of insomnia and depression, and in line with the diagnostic criteria of heart-gallbladder qi deficiency syndrome diagonsis criteria; (5)The cumulative score of 7 factors of Pittsburgh Sleep Quality Index Scale(PSQI) was >7 points; (6)Voluntary participation and signed informed consent.

Exclusion criteria

Exclusion criteria: (1)Secondary insomnia,environmental sleep disorders, etc. obstructive sleep apnea-hypopnea syndrome; depression caused by depression secondary to other mental and physical dieases. (2)Patients with serious primary heart, liver, lungs, kidneys, blood or serious diseases affecting their survival, mental illness or serious suicidal tendencies. (3)Screening for alcohol dependence and drug abuse within the perivous year; (4)Pregnant and lactating women; (5)Participants who participated or participating in other drug clinical trials in the 3 months prior to enrollment; (6)Patients with other conditions deemed by the investigator to be ineligible for screening.

Design outcomes

Primary

MeasureTime frame
REM sleep latency;REM sleep time;REM sleep density;

Secondary

MeasureTime frame
Pittsburgh Sleep Quality Index Scale;TCM syndrome grading quantified intergral;Hamilton Depression Scale;sleep latency;sleep time;sleep efficiency;wake time after sleep onset;NREM1 sleep as a percentage of total sleep time;NREM3 sleep as a percentage of total sleep time;

Countries

China

Contacts

Public ContactQing Ye

Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Yeqing1982889@163.com+86 136 3630 4576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026